Raj Reddy
Chief Executive Officer Canary Limited
Dr. Raj Reddy is a pharmacologist and the Chief Executive Officer of Canary Cure Therapeutics, a biotechnology company pioneering dual siRNA medicines for obesity and metabolic disease. Over his career in specialty pharma, Dr. Reddy has led programs worth more than $500 million spanning hematology, oncology, inflammatory disease, RNA therapeutics, metabolic disorders, and genetics. He is the inventor on more than 25 patents in genetics and the author of pivotal studies in metabolic disease and gene-silencing therapeutics, including the foundational work behind Canary Cure’s lead program, CCT-217. Under his leadership, Canary has advanced CCT-217 as a first-in-class dual siRNA therapy that reprograms adipose tissue to deliver durable, muscle-sparing weight loss and broad cardiometabolic benefits with only twice-yearly dosing. Dr. Reddy’s mission is to redefine obesity treatment by moving beyond appetite suppression toward true metabolic reprogramming, positioning RNAi as the next major wave in obesity and cardiometabolic medicine.
Seminars
The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:
- Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
- Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
- Strategizing how to position pipelines at the forefront of next-gen RNAi innovation
- Exploring advances in extrahepatic dual RNAi delivery to enable targeted delivery to adipose tissue for treating the root cause of metabolic disease
- Demonstrating preclinical efficacy through human adipocyte validation to provide robust proof-of-concept and de-risk clinical translation
- Discussing how dual-target RNAi can expand beyond obesity into MASLD/MASH and cardiometabolic health to systemically improve metabolic parameters
- Positioning multi-target RNAi as the next wave beyond appetite suppression to move beyond the limitations of central appetite suppression and offer a more durable, tissue-specific, and holistic solution for sustainable weight loss
